|
IL71691A
(en)
|
1984-04-27 |
1991-04-15 |
Yeda Res & Dev |
Production of interferon-ypsilon
|
|
US5128326A
(en)
|
1984-12-06 |
1992-07-07 |
Biomatrix, Inc. |
Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
|
|
US5266561A
(en)
|
1988-01-11 |
1993-11-30 |
Amylin Pharmaceuticals, Inc. |
Treatment of type 2 diabetes mellitus
|
|
SE509359C2
(sv)
*
|
1989-08-01 |
1999-01-18 |
Cemu Bioteknik Ab |
Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
|
|
WO1991006287A1
(en)
|
1989-11-06 |
1991-05-16 |
Enzytech, Inc. |
Protein microspheres and methods of using them
|
|
US5387742A
(en)
|
1990-06-15 |
1995-02-07 |
Scios Nova Inc. |
Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease
|
|
US5408038A
(en)
|
1991-10-09 |
1995-04-18 |
The Scripps Research Institute |
Nonnatural apolipoprotein B-100 peptides and apolipoprotein B-100-apolipoprotein A-I fusion peptides
|
|
FR2686899B1
(fr)
*
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
|
US5912015A
(en)
|
1992-03-12 |
1999-06-15 |
Alkermes Controlled Therapeutics, Inc. |
Modulated release from biocompatible polymers
|
|
US5420112A
(en)
|
1992-06-12 |
1995-05-30 |
Lewis; Michael E. |
Prevention and treatment of peripheral neuropathy
|
|
US5541094A
(en)
|
1992-09-25 |
1996-07-30 |
E. I. Du Pont De Nemours And Company |
Glyoxylic acid/aminomethylphosphonic acid mixtures prepared using a microbial transformant
|
|
US5877399A
(en)
|
1994-01-27 |
1999-03-02 |
Johns Hopkins University |
Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
|
|
US6187992B1
(en)
|
1994-12-05 |
2001-02-13 |
Merck & Co., Inc. |
Transgenic mouse having a disrupted amyloid precursor protein gene
|
|
EP0850051A2
(en)
|
1995-08-31 |
1998-07-01 |
Alkermes Controlled Therapeutics, Inc. |
Composition for sustained release of an agent
|
|
US6194177B1
(en)
|
1996-02-20 |
2001-02-27 |
Applied Research Systems Ars Holding N.V. |
DNA encoding a hybrid heterodimeric protein
|
|
EP0906090A1
(en)
|
1996-03-15 |
1999-04-07 |
Somerset Pharmaceuticals, Inc. |
Method for preventing and treating peripheral neurophathy by administering selegiline
|
|
US6358752B1
(en)
|
1996-09-27 |
2002-03-19 |
Cornell Research Foundation, Inc. |
Liposome-enhanced test device and method
|
|
WO1998029544A1
(en)
|
1996-12-26 |
1998-07-09 |
Kyowa Hakko Kogyo Co., Ltd. |
Novel peptide, novel dna, and novel antibody
|
|
US6127598A
(en)
|
1997-07-25 |
2000-10-03 |
The Regents Of The University Of California |
NKX-2.2 and NKX-6.1 transgenic mouse models for diabetes, depression, and obesity
|
|
US5989463A
(en)
|
1997-09-24 |
1999-11-23 |
Alkermes Controlled Therapeutics, Inc. |
Methods for fabricating polymer-based controlled release devices
|
|
SE512663C2
(sv)
|
1997-10-23 |
2000-04-17 |
Biogram Ab |
Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
|
|
AU3463699A
(en)
|
1998-04-03 |
1999-10-25 |
Phylos, Inc. |
Addressable protein arrays
|
|
US7060479B2
(en)
|
1999-12-08 |
2006-06-13 |
Serono Genetics Institute, S.A. |
Full-length human cDNAs encoding potentially secreted proteins
|
|
US20030055231A1
(en)
|
1998-10-28 |
2003-03-20 |
Jian Ni |
12 human secreted proteins
|
|
EP1171778B1
(en)
|
1999-04-22 |
2006-03-01 |
Liposcience, Inc. |
Nmr-method for determining the risk of developing type 2 diabetes
|
|
WO2001001251A1
(en)
|
1999-06-30 |
2001-01-04 |
Microsoft Corporation |
Restoration of a computer to a previous state
|
|
US6569832B1
(en)
|
1999-11-12 |
2003-05-27 |
Novo Nordisk A/S |
Inhibition of beta cell degeneration
|
|
US6716626B1
(en)
|
1999-11-18 |
2004-04-06 |
Chiron Corporation |
Human FGF-21 nucleic acids
|
|
US6406853B1
(en)
|
1999-12-23 |
2002-06-18 |
The Regents Of The University Of California |
Interventions to mimic the effects of calorie restriction
|
|
US20060160181A1
(en)
|
2000-02-15 |
2006-07-20 |
Amgen Inc. |
Fibroblast Growth Factor-23 molecules and uses thereof
|
|
CA2398603A1
(en)
|
2000-02-15 |
2001-08-23 |
Amgen, Inc. |
Fibroblast growth factor-23 molecules and uses thereof
|
|
JP2006238894A
(ja)
|
2000-02-15 |
2006-09-14 |
Amgen Inc |
線維芽細胞成長因子−２３分子およびその使用
|
|
AU2001249125A1
(en)
|
2000-03-08 |
2001-09-17 |
Chiron Corporation |
Human fgf-23 gene and gene expression products
|
|
ES2340662T3
(es)
|
2000-07-19 |
2010-06-08 |
Advanced Research And Technology Institute |
Factor de crecimiento de fibroblastos (fgf23) nuevo procedimiento para el uso.
|
|
CA2436661A1
(en)
|
2001-01-30 |
2002-08-08 |
Regeneron Pharmaceuticals, Inc. |
Novel nucleic acid and polypeptide molecules
|
|
US7588757B2
(en)
|
2001-03-14 |
2009-09-15 |
Genzyme Corporation |
Methods of treating Parkinson's disease using recombinant adeno-associated virus virions
|
|
CA2443719A1
(en)
|
2001-04-26 |
2002-11-07 |
Geneprot, Inc. |
Human fibroblast growth factor-related compositions
|
|
EP1327443A1
(en)
|
2001-12-21 |
2003-07-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Therapeutic or preventing agent for the diseases caused by a decrease in the expression level of the klotho protein
|
|
US20050004348A1
(en)
|
2002-12-23 |
2005-01-06 |
Miyamoto Ken-Ichi |
Novel type II Na/Pi cotransporters and type II Na/Pi cotransporter expression regulatory factors
|
|
JP2007531707A
(ja)
|
2003-10-15 |
2007-11-08 |
ピーディーエル バイオファーマ， インコーポレイテッド |
ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変
|
|
US8420088B2
(en)
|
2008-01-28 |
2013-04-16 |
Novartis Ag |
Methods and compositions using FGF23 fusion polypeptides
|
|
TW200936156A
(en)
|
2008-01-28 |
2009-09-01 |
Novartis Ag |
Methods and compositions using Klotho-FGF fusion polypeptides
|
|
US20170233446A1
(en)
|
2008-01-28 |
2017-08-17 |
Novartis Ag |
Methods and compositions using klotho-fgf fusion polypeptides
|
|
US20110015345A1
(en)
|
2008-03-19 |
2011-01-20 |
Ambrx, Inc. |
Modified FGF-23 Polypeptides and Their Uses
|
|
JP5878757B2
(ja)
|
2008-10-10 |
2016-03-08 |
アムジエン・インコーポレーテツド |
Ｆｇｆ２１変異体およびその使用
|
|
US8461111B2
(en)
|
2009-05-20 |
2013-06-11 |
Florida State University Research Foundation |
Fibroblast growth factor mutants having improved functional half-life and methods of their use
|
|
US20110195077A1
(en)
|
2010-01-29 |
2011-08-11 |
Novartis Ag |
Methods and compositions using fgf23 fusion ppolypeptides
|
|
WO2013027191A1
(en)
*
|
2011-08-25 |
2013-02-28 |
Novartis Ag |
Methods and compositions using fgf23 fusion polypeptides
|
|
SE1450131A1
(sv)
|
2011-10-21 |
2014-05-07 |
Abbvie Inc |
DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
|
|
US10588980B2
(en)
|
2014-06-23 |
2020-03-17 |
Novartis Ag |
Fatty acids and their use in conjugation to biomolecules
|